Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CCA, FVT

Regulus Therapeutics to Participate in Upcoming Investor Conferences


SAN DIEGO, Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in two upcoming investor conferences.

Details are as follows:

A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at www.regulusrx.com and archived for 30 days following the presentation date.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Forward-Looking Statements

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including the expected timing for initiating clinical studies, the expected timing for reporting topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

SOURCE Regulus Therapeutics, Inc


These press releases may also interest you

at 18:45
The global sexually transmitted disease (STD) testing market size is set to grow by USD 29,988.27 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 5.46% during the forecast period. This...

at 18:30
The global endocrinology drugs market size is set to grow by USD 36551.24 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.82% during the forecast period. This report provides...

at 18:05
Puma Biotechnology, Inc. , a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster...

at 18:00
The global smoking cessation and nicotine de-addiction market size is set to grow by USD 24,529.75 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 12.59% during the forecast period....

at 17:44
We need to address health inequities and promote positive mental health for people across the country, particularly for those who face disproportionate challenges accessing mental health supports due to racism and discrimination or because of their...

at 17:05
Dr. Shervin Naderi, the founder of The Naderi Center for Plastic Surgery & Dermatology in Virginia and Maryland, has been chosen again as one of Washingtonian Magazine's Top Doctors for 2022. Dr. Naderi was nominated by his colleagues as a Top Doctor...



News published on 2 september 2022 at 16:05 and distributed by: